Our team of researchers is a dedicated and diverse team of physicians and allied health professionals with expertise in the treatment of HIV, hepatitis B, hepatitis C, Nonalcoholic Steatohepatitis (NASH) and HIV prevention (PrEP). Our research institute has conducted nearly 200 clinical trials, studying the newest therapies available from the leading international biopharmaceutical companies.
Our current team includes 4 Sub-Investigators, 1 Clinical Research Director, 5 Clinical Research Coordinators, 4 Clinical Research Associates, 4 Research Assistants, and 1 Regulatory Specialist working under the supervision of the Principal Investigator. Our team works on pharmaceutical-sponsored clinical trials in addition to publishing results from Investigator-Initiated Studies.
First FibroScan in Los Angeles
Dr. Ruane was the first to bring the non-invasive FibroScan technology to Los Angeles in 2013. FibroScan allows for painless examination of the liver, helping to avoid biopsies in many cases.
First large scale genotype 4 study
The Ruane team was the first to conduct a large scale hepatitis C genotype 4 study among the Egyptian population.
Highest enroller in the PrEP DISCOVER study
Our research site provided free STD testing and trial medication to more than 400 patients in the PrEP DISCOVER Study.